You are here: Industry Insights > ALIMTA

News List

Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC prnasia
January 13, 2020
The safety profile of sintilimab in this trial was consistent with previously reported studies, and no new safety signals were identified.
Mylan generic of lung cancer drug Alimta approved europeanpharmaceuticalreview
September 04, 2019
Mylan NV’s generic version Eli Lilly and Co’s lung cancer drug, Alimta, has been given tentative approval by the FDA.
US court rules in favour of Lilly in Alimta® patent lawsuit europeanpharmaceuticalreview
August 13, 2019
The US District Court has ruled in favour of Eli Lilly in the Alimta patent lawsuit against Dr. Reddy’s Laboratories and Hospira, Inc.
FDA expands Lilly's ALIMTA Label biospectrumasia
February 02, 2019
This indication is approved based on data from Merck's Phase 3 KEYNOTE-189 trial
EC green-lights MSD’s Keytruda combo for lung cancer pharmatimes
November 27, 2018
The European Commission has approved MSD’s Keytruda for use in combination with Eli Lilly’s Alimta and platinum-based chemotherapy for the first-line treatment of some advanced lung cancers.
Global Metastatic Cancer Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024 biospace
March 30, 2018
The global metastatic cancer therapy market is growing significantly with increasing sales of some major drugs like an Eli Lilly product Alimta with average sales of US$ 2.5 Billion per yea